NCT06136897View on ClinicalTrials.gov

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 23, 2017

Primary Completion Date

November 3, 2021

Study Completion Date

December 31, 2025

Conditions
Malignant Solid Neoplasm
Interventions
PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Echocardiography Test

Undergo ECHO

BIOLOGICAL

Pertuzumab

Given IV

PROCEDURE

Radiologic Examination

Undergo radiologic evaluation

BIOLOGICAL

Trastuzumab

Given IV

Trial Locations (1)

19103

ECOG-ACRIN Cancer Research Group, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT06136897 - Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) | Biotech Hunter | Biotech Hunter